Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:1–7.
   Web of Science ®Google Scholar
• Kargi A, Bisgin A, Yalcin AD, et al. Increased serum s-TRAIL level in newly diagnosed Stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age ad smoking. Asian Pac J CancerPrev. 2013;14:4819–4822.
   Google Scholar
• Spierings DCJ, de Vries EGE, Timens W, et al. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res. 2003;9:3397–3405.
   PubMed Web of Science ®Google Scholar
• Pore MM, Hiltermann TJN, Kruyt FAE. Targeting apoptosis pathways in lung cancer. Cancer Letters. 2013;332:359–368.
   PubMed Web of Science ®Google Scholar
• Fujimoto J, Wistuba II. Current concepts on the molecular pathology of non-small cell lung carcinoma. SeminDiagnPathol. 2014;31:306–313.
   Google Scholar
• Luo J, Xiong J, Wu J, et al. Genetic polymorphisms and haplotypes of TRAIL gene correlate with NSCLC susceptibility in a group of Chinese patients. Int J ClinExp Med. 2015;8:16223–16230.
   Google Scholar
• Jablonska E, Jablonski J, Marcinczyk M, et al. The release of soluble forms of TRAIL and DR5 by neutrophils of oral cavity cancer patients. Folia HistochemicaEtCytobiologica. 2008;46:177–183.
   Web of Science ®Google Scholar
• Herbeuval J, Lambert C, Sabido O, et al. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis. J Natl Cancer Ins. 2003;95:611–621.
   Google Scholar
• Chen J, Bozza WP, Di X, et al. H-Ras regulation of TRAIL death receptor mediated apoptosis. Oncotarget. 2014;5:5125–5137.
   Google Scholar
• Walczak H. Death receptor–ligand systems in cancer, cell death, and inflammation cold. Spring HarbPerspectBiol. 2013;5:1–18.
   Web of Science ®Google Scholar
• Verim A, Turan S, Farooqi AA, et al. Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand [TRAIL], TRAIL receptor and sTRAIL levels. Asian Pac J Cancer Prev. 2014;15:10697–10703.
   Google Scholar
• Yaylım I, Ozkan NE, Turan S, et al. sTRAIL serum levels and TRAIL 1595 genotypes: associations with progress and prognosis of colorectal carcinoma. J Cancer Ther. 2012;3:941–947.
   Google Scholar
• Yildiz Y, Yaylim-Eraltan I, Arikan S, et al. Is there any correlation between TNF-related apoptosis-inducing ligand [TRAIL] genetic variants and breast cancer? Arch Med Sci. 2010;6:932–936.
   Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, et al. TRAIL in cancer therapy: present and future challenges. Expert OpinTher Targets. 2007;11:1299–1314.
   PubMed Web of Science ®Google Scholar
• Prasad S, Hye Kim J, Gupta SC, et al. Targeting death receptors for TRAIL by agents designed by Mother Nature. Trends Pharmacol Sci. 2014 Oct;35:520–536. .
   PubMed Web of Science ®Google Scholar
• Toiyama D, Takaha N, Shinnoh M, et al. Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma. Mol Clin Oncol. 2013;1:69–74.
   Google Scholar
• Heredia-Galvez B, Ruiz-Cosano J, Torres-Moreno D, et al. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Ann Hematol. 2014;93:243–247.
   PubMed Web of Science ®Google Scholar
• Schneider-Brachert W, Heigl U, Ehrenschwender M. Membrane trafficking of death receptors: implications on Signalling.. Int J. Mol. Sci. 2013;14:14475–14503.
   PubMed Web of Science ®Google Scholar
• Pal R, Gochhait S, Chattopadhyay S, et al. Functional implication of TRAIL −716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treat. 2011;126:333–343.
   Web of Science ®Google Scholar
• Wang C, Xu S, Yi F, et al. Tumor necrosis factor-related apoptosis inducing ligand gene polymorphisms are correlated with gastric cancer in central China. Pharm Res. 2015;32:762–768.
   Web of Science ®Google Scholar
• Timirci-Kahraman O, Ozkan NE, Turan S, et al. Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand [TRAIL] and death receptor [DR4] genes contribute to susceptibility to bladder cancer. Genet Test Mol Biomarkers. 2015;19:309–315.
   Web of Science ®Google Scholar
• Mi YY, Li JM, Shao N, et al. TRAIL gene polymorphism and genetic susceptibility to prostate cancer in the Chinese Han population of Nanjing. Zhonghua Nan KeXue. 2011;17:242–246.
   Google Scholar
• Macher-Goeppinger S, Aulmann S, Tagscherer KE, et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand [TRAIL] and TRAIL receptors in renal cell cancer. Clin Cancer Res. 2009;15:650–659.
   Web of Science ®Google Scholar
• Yu MY, Zhao PQ, Yan XH, et al. Association between the TRAIL single nucleotide polymorphism rs1131580 and type 2 diabetes mellitus in a Han Chinese population. Genet. Mol. Res. 2013;12:3455–3464.
   Web of Science ®Google Scholar
• Xu S, Liang T, Li S. Correlation between polymorphism of TRAIL gene and condition of intervertebral disc degeneration. Med SciMonit. 2015;21:2282–2287.
   Web of Science ®Google Scholar
• Kikuchi S, Miyagishi R, Fukazawa T, et al. TNF-related apoptosis inducing ligand [TRAIL] gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol. 2005;167:170–174.
   PubMed Web of Science ®Google Scholar
• Hu D, Xia S, Shao X, et al. Association of ulcerative colitis with TNF-related apoptosis inducing ligand [TRAIL] gene polymorphisms and plasma soluble TRAIL levels in Chinese Han population. European. Rev Med Pharmacological Sci. 2015;19:467–476.
   Web of Science ®Google Scholar
• Yan X, Xu L, Qi J, et al. sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics. 2009;61:551–556.
   PubMed Web of Science ®Google Scholar
• Stegehuisa JH, de Wilt LHAM, de Vriesa EGE, et al. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resistance Updates. 2010;13:2–15.
   Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated. cells. Nucleic Acids Research. 1988;16:1215.
   PubMed Web of Science ®Google Scholar
• Bray F, Forman D. Lung Cancer. In: Jemal A, Vineis P, Bray F, et al., Eds. CanserAtlas. 2rd ed. Atlanta, Georgia: American Cancer Society; 2014. p. 38–39.
   Google Scholar
• Brambilla E, TravisWD. Lung Cancer. Stewart BW, Wild CP (Eds):World Cancer Reports 2014. WHO Situation Reports, Lyon, 2014, IARC Publications  pp. 350-352.
   Google Scholar
• McErlean A, Ginsberg MS. Epidemiology of Lung Cancer. SeminRoentgenol. 2011;46:173–177.
   Google Scholar
• Steliga MA, Dresler CM. Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. SurgOncolClin N Am. 2011;20:605–618.
   Web of Science ®Google Scholar
• Du H, Bai B, Qiu Y, et al. Association between TRAIL gene polymorphisms and the susceptibility and severity of lumbar disc degeneration. Int J ClinExpPathol. 2015;8:7415–7420.
   Google Scholar
• Soleimani A, Rafatpanah H, Nikpoor AR, et al. Tumor necrosis factor-related apoptosis-inducing ligand gene polymorphisms and hepatitis B virus infection Jundishapur. J Microbiol. 2015;8:1–6.
   Web of Science ®Google Scholar
• Piras-Straub K, Khairzada K, Trippler M, et al. TRAIL expression levels in human hepatocellular carcinoma have implications for tumor growth, recurrence and survival. Int. J. Cancer. 2015;136:154–160.
   Web of Science ®Google Scholar
• vonKarstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017;17:352–366.
   Web of Science ®Google Scholar